Document is current
Any future updates will be listed below
-
Authors
Zhang, Haijiao https://orcid.org/0000-0002-0749-9866
Nakauchi, Yusuke https://orcid.org/0000-0002-6943-3811
Köhnke, Thomas
Stafford, Melissa
Bottomly, Daniel
Thomas, Rozario
Wilmot, Beth
McWeeney, Shannon K. https://orcid.org/0000-0001-8333-6607
Majeti, Ravindra
Tyner, Jeffrey W. https://orcid.org/0000-0002-2133-0960
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1K99CA237630-01, 5K99CA237630-02, 1U01CA217862-01, 1U54CA224019-01, 3P30CA069533-18S5, 1R01CA188055, 5R00CA151457-04, 1R01CA183947-01)
Medical research foundation
The Leukemia and Lymphoma Society
Gabrielle’s Angel Foundation for Cancer Research
- License Information
-
More Information
Article History
Received: 18 September 2019
Accepted: 17 July 2020
First Online: 18 August 2020
Competing interests
: J.W.T. received research support from Aptose, Array, AstraZeneca, Constellation, Genentech, Gilead, Incyte, Janssen, Seattle Genetics, Syros and Takeda. R.M. is on the Scientific Advisory Board of Kodikaz Therapeutic Solutions Inc. and Zenshine Pharmaceuticals Inc., and is an inventor on a number of patents related to CD47 cancer immunotherapy licensed to Gilead Sciences, Inc.
